Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
As part of the fight against rare diseases discussed extensively at European level, the 'All United for MG"1 coalition, a group of patient associations and representatives2, is organising the
Ultomiris, the generalised myasthenia gravis (gMG) treatment developed by multinational pharmaceutical giant AstraZeneca PLC (LSE:AZN), has been approved.